Introduction Diabetes and pregnancy can be associated in two ways: pregnancy that occurs in women who are already diabetic (diabetes of pre-gestational origin); and diabetes that occur in women who are already pregnant [gestational diabetes mellitus (GDM) (O'sullivan 1961)]. Patients with previous GDM history have higher risk of developing diabetes outside of pregnancy. Accumulating literature had suggested that adiponectin plays a role in the pathophysiology of this metabolic syndrome, and several of the common single nucleotide polymorphisms (SNP) in adiponectin gene have been identified in type 2 diabetes. Thus, one of the commonly found SNP was studied to determine its association with GDM. Objective To identify the association of SNP45TG with GDM. Methods This is a cross-sectional study involving pregnant mothers of\18 gestational weeks, who were recruited from three local antenatal clinics in Selangor, Malaysia. Their genomic DNA was extracted from EDTA treated whole blood using commercialized kit. Adiponectin gene was amplified through conventional PCR and SNP was detected using restriction enzyme SmaI. Plasma adiponectin level, fructosamine level and HbA 1c percentage were also examined. Results Among the 79 antenatal patients recruited, 53 patients were normal and 26 were diagnosed with GDM.
Introduction
The association between diabetes and pregnancy can be broadly classified into diabetes of pre-gestational origin, which occurs in originally diabetic women who become pregnant; and gestational diabetes mellitus (GDM), termed by O' Sullivan (1961), in which pregnant women subsequently develop diabetes during gestation period. GDM appears to be the most common metabolic disorder during the period of pregnancy, and the cases of GDM are increasing in several populations since the last decade [1, 2] . In addition, women who had previous gestational diabetes history have increased risk of developing diabetes outside pregnancy, but the type of diabetes that occurs after gestational diabetes has not been investigated. Nevertheless, type 2 diabetes appears to predominate as gestational diabetes and type 2 diabetes shared almost the same extent of risk factors such as obesity.
Adiponectin which is one of the adipocyte-secreted hormones has recently been reported to play a role in the pathophysiology of metabolic disorder, notably in type 2 diabetes mellitus. Experimental findings reported that adiponectin possesses multivalent functions including antiatherogenic, insulin-sensitizing, lipid-oxidation enhancing and vasodilatory properties [3] . Decreased plasma adiponectin levels have been reported parallel to the occurrence of insulin resistance and diabetes in rhesus monkeys [4] . Besides, recombinant adiponectin was reported to decrease serum glucose level in normal and diabetic rodents without prior stimulation of insulin secretion [5] . Furthermore, patients diagnosed with type 2 diabetes mellitus exhibit significantly lower level of plasma adiponectin as compared to normal patients [6] and predisposition to the development of type 2 diabetes mellitus in patients with lower concentration of plasma adiponectin is observable [7] .
A particular single nucleotide polymorphism (SNP) in adiponectin gene which is also known as SNP45 in exon 2 is one of the most commonly found SNPs in adiponectin gene and it has been reported to be associated and closely correlated with type 2 diabetes [8] [9] [10] . SNP45 in adiponectin gene was found to be associated with obesity and other features of insulin resistance syndrome [9] , suggesting these SNPs could probably influence the concentration of plasma adiponectin and subsequently insulin sensitivity. SNP in adiponectin gene was found to have a significant association with increased BMI accompanied with reduced insulin sensitivity in individuals without a family history of diabetes [11] . Our main objective was to identify the association of SNP45 in adiponectin gene with GDM.
Methodology
The study protocol was approved by the ethics board at Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, and the Ministry of Health, Malaysia. All participants gave written informed consent. Antenatal patients attending the clinic (Polyclinic Bangi, Polyclinic Kajang, or Polyclinic Seri Kembangan) for the first time upon pregnancy and below 18 weeks of gestational age were recruited. Antenatal patients who were pre-diagnosed of type 1 or type 2 diabetes mellitus were excluded from the study. A total volume of 3 ml peripheral blood was drawn by trained phlebotomist during the first time approach with the patients.
Antenatal patients during their following visit to the clinic underwent maternal glucose tolerance test (OGTT). Indications for OGTT were: (1) history of diabetes in a first degree relative, (2) glycosuria in fasting urine sample, (3) diabetes in previous pregnancy, (4) maternal weight more than 80 kg, (5) previous baby weighing more than 4 kg, (6) previous unexplained intrauterine death or early neonatal death, (7) congenital abnormality in previous pregnancy, (8) congenital abnormality in current pregnancy, and (9) polyhydramnios.
Patients were categorized into three different diagnosis groups as in Table 1 according to OGTT results. However, patients who had impaired glucose tolerance were categorized into gestational diabetic patients for further analysis in this study.
Protocol of screening and diagnosis of GDM were adapted from the guidelines and protocols from Department of Obstetrics and Gynaecology, Hospital Kuala Lumpur, Malaysia, which follows the WHO criteria for diagnosis of diabetes or impaired glucose tolerance using a 75 g oral glucose challenge test (WHO 1980) . DNA was extracted from EDTA treated whole blood using QIAamp Ò DNA Blood Midi kit from Qiagen. The extracted genomic DNA was stored at -20°C prior to PCR. Adiponectin gene was amplified using Adipo45TG forward primer (5 0 -TCTCTCCATGGCTGACAGTG-3 0 ) and Adipo45TG reverse primer (5 0 -CCTTTCTCACCCTTCTC ACC-3 0 ) [9] . PCR was performed on DNA (25-30 ng) using Taq PCR kit (New England BioLabs Adiponectin SNP45 was detected through digestion of PCR product by the restriction enzyme SmaI with the specific recognition site of 5 0 …CCCGGG…3 0 . Digestion of PCR products (5-10 lg) was performed in 10 ll containing 19 NEBuffer 4 (50 mM potassium acetate, 20 mM Trisacetate, 10 mM magnesium acetate, 1 mM DTT, at pH 7.9) and 1 U/ll of the restriction enzyme SmaI. The reaction was incubated at 25°C for 24 h. Reaction was then inactivated by incubation at 65°C for 20 min. The enzyme concentration was increased and the incubation time was prolonged to ensure complete digestion of the PCR products. Results were visualized through 1.5% agarose gel electrophoresis (Figs. 1, 2 ). Expected size of the products after restriction digestion was: (1) TT homozygous genotype: a single band of 250 bp (undigested), (2) TG heterozygous genotype: Hemoglobin level was measured using EDTA-treated whole blood sample using the Sysmex KX-21 Hematology Analyzer. Plasma adiponectin level was measured using a commercialized ELISA assay kit from Mercodia, with sensitivity of up to 1.25 ng/ml, and assay range between 5 and 300 ng/ml.
Results were analyzed using SPSS software version 15.0. Analysis of association of adiponectin SNP45 with GDM was done using Chi-square test. Comparisons of different variables between groups were done using oneway ANOVA. Table 2 .
Results

A total of
Our data show that TG/GG genotype of SNP45 in adiponectin gene is significantly more frequent than TT genotype of gestational diabetic patients than in normal patients (v 2 = 4.038; P = 0.044). Comparing the distribution of allele T and allele G in SNP45 among the normal and gestational diabetic patients, data from this study show that G allele in SNP45 of adiponectin gene is significantly more frequent in gestational diabetic patients than normal patients (v 2 = 4.324; P = 0.038) (Fig. 3) . The plasma adiponectin level during early pregnancy is significantly lower in gestational diabetic patients than in normal patients (P \ 0.05). Normal patients that carry TT genotype of SNP45 in adiponectin gene apparently have the highest level of plasma adiponectin. Meanwhile gestational diabetic patients that carry TG/GG genotype have the lowest level of plasma adiponectin. Mean difference of plasma adiponectin level between these two groups is statistically significant (P \ 0.05) ( Table 3) . We found no significant difference in BMI, Hb level, plasma fructosamine level and HbA 1c percentage during early pregnancy between gestational diabetic patients and normal patients (Table 4 ). However, among normal patients, patients that carry TG/GG genotype of SNP45 in adiponectin gene have a significantly higher BMI as compared to patients that carry TT genotype (P \ 0.05). Among the patients that carry TT genotype of SNP45 in adiponectin gene, the gestational diabetic patients have a significantly higher BMI when compared to the normal patients (Fig. 4) .
Discussion
GDM has an increasing prevalence during the last decade in several populations, and has been claimed to be the causative factor of several adverse pregnancy outcomes commonly, macrosomia [12] and plausibly, congenital malformation [13] . Low plasma adiponectin concentrations, which is also termed as hypoadiponectinemia, has been reported to be associated with type 2 diabetes [7, 14, 15] ; and recently, to the extent of gestational diabetes mellitus [14, [16] [17] [18] [19] [20] [21] . Our finding was parallel with the previous reports as we found a significant lower level of plasma adiponectin in patients diagnosed with GDM compared with patients who had normal OGTT result. During early trimester, patients' BMI was not significantly different between GDM and normal patients. Plasma fructosamine level and HbA 1c percentage which serve to monitor blood glucose control showed no significant difference between GDM and normal patients during early trimester, indicating that antenatal patients probably had normal glucose metabolism during early pregnancy, and that insulin resistance due to normal physiological changes of pregnancy actuate during mid-pregnancy as gestation progressed. However, a significant difference in plasma adiponectin level between GDM and normal patients was Fig. 4 Comparison of BMI between normal patients and GDM patients with differences in genotype. *Significant at P \ 0.05 observable during early trimester before any other manifestations of this metabolic disorder could be detected, suggesting that low circulating plasma adiponectin concentrations could represent a biomarker or one of the risk factors for GDM and thus this warrants further evaluation. Throughout the years, numerous findings unequivocally inferred that low circulating plasma adiponectin concentrations were significantly associated with diminished insulin sensitivity. Ever since scientists have mapped diabetes susceptibility locus of chromosome 3q27 [22] [23] [24] , in which the adiponectin gene was located, genetic variation in adiponectin gene granted attention as it might predispose humans to insulin resistance and the metabolic syndrome. T/G polymorphism of SNP45 in exon 2 and G/T polymorphism of SNP276 in intron 2 appeared to be the variants that were consistently being reported [9, 10, [25] [26] [27] [28] [29] [30] . The adiponectin SNP45 was frequently being reported in type 2 diabetes mellitus, and our findings revealed the association between adiponectin SNP45 with gestational diabetes mellitus. The SNP45 was reported to be significantly associated with risk of type 2 diabetes mellitus in Japanese [8] , but the association was not found in French population [31] suggesting adiponectin SNP45 might be associated with the metabolic syndrome in variable roles in different ethnic group. Further evaluation is warranted as our local population is multi-ethnic.
Our findings revealed that GDM patients who carried TG/GG genotype of adiponectin SNP45 have a significantly lower plasma adiponectin levels compared to normal patients who carried TT genotype, denoting a possible role of TG/GG genotype in plasma adiponectin levels. Even though it has been reported previously by Li et. al. [10] that adiponectin SNP45 is associated with obesity, our finding exhibited inconsistent results; however, significant difference in patients' BMI was observable in different genotype groups, it can be postulated that SNP45 in adiponectin could possibly be associated with increased rate of weight gain in antenatal patients and lowered plasma adiponectin level subsequently the risk of GDM, which warrant further investigation.
Limitation
Our study revealed a significant association between adiponectin SNP45 and GDM, and possible role of this SNP in plasma adiponectin concentration. However, a limitation of this study is that the mRNA expression level as well as the protein expression of adiponectin gene is yet to be studied. Besides, our study was limited to reveal the implication of low circulating plasma adiponectin concentration with insulin sensitivity in GDM patients. Nevertheless, it should not be neglected that reduced insulin sensitivity that was triggered by normal physiological changes during pregnancy could influence the findings.
Conclusion
We conclude that gestational diabetic patients have significantly lower plasma adiponectin levels than normal patients during early trimester. Adiponectin SNP45 was found to be significantly associated with GDM. Gestational diabetic patients who carried TG/GG genotype in adiponectin SNP45 have lowered level of plasma adiponectin as compared to other groups indicating a role of adiponectin SNP45 in circulating plasma adiponectin levels and its subsequent risk of GDM.
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